EGFR and intestinal cancer: For patients with metastatic, EGFR antibody-resistant bowel cancers, a combination of trastuzumab and Lapatinib looks promising, but it is unclear whether the same combination is better than an EGFR antibody for patients who have never been treated for metastatic bowel cancer yet [5].